Cartesian Therapeutics, Inc.
RNAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $265,750 | $269,935 | $341,397 | $463,996 |
| - Cash | $143,384 | $160,324 | $180,434 | $212,610 |
| + Debt | $12,603 | $13,349 | $14,066 | $13,984 |
| Enterprise Value | $134,969 | $122,960 | $175,029 | $265,370 |
| Revenue | $452 | $298 | $1,100 | -$759 |
| % Growth | 51.7% | -72.9% | 244.9% | – |
| Gross Profit | -$12,345 | $298 | $1,100 | -$759 |
| % Margin | -2,731.2% | 100% | 100% | 100% |
| EBITDA | -$35,296 | $16,475 | -$20,733 | -$9,480 |
| % Margin | -7,808.8% | 5,528.5% | -1,884.8% | 1,249% |
| Net Income | -$35,902 | $15,886 | -$17,710 | -$10,253 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | 1,350.9% |
| EPS Diluted | -1.38 | 0.6 | -0.68 | -0.069 |
| % Growth | -330% | 188.2% | -885.5% | – |
| Operating Cash Flow | -$15,600 | -$17,521 | -$23,108 | -$7,002 |
| Capital Expenditures | -$1,292 | -$2,595 | -$1,075 | -$705 |
| Free Cash Flow | -$16,892 | -$20,116 | -$24,183 | -$7,707 |